RecruitingPhase 2NCT07384234

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: an Exploratory Study

Sponsor

Ruijin Hospital

Enrollment

60 participants

Start Date

Apr 24, 2026

Study Type

INTERVENTIONAL

Conditions

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Summary

This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Capecitabine, a drug called Oxaliplatin, and others for people with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-1701

SHR-1701, 1800mg, Q3w

DRUGCapecitabine

Capecitabine, Q3W

DRUGS-1

S-1, Q3W

DRUGPaclitaxel

Paclitaxel,Q3W

DRUGOxaliplatin

Oxaliplatin, Q3W

Locations(2)

Changhai Hospital

Shanghai, Shanghai Municipality, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07384234

Related Trials

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

NCT069621376 locations

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

NCT049822761 location